Human epididymis protein 4 promotes P‑glycoprotein‑mediated chemoresistance in ovarian cancer cells through interactions with Annexin II

Liu,Qing; Liu,Da-Wo; Zheng,Ming-Jun; Deng,Lu; Wang,Hui-Min; Jin,Shan; Liu,Juan-Juan; Hao,Ying-Ying; Zhu,Lian-Cheng; Lin,Bei

doi:10.3892/mmr.2021.12135

Human epididymis protein 4 promotes P‑glycoprotein‑mediated chemoresistance in ovarian cancer cells through interactions with Annexin II

Authors:
- Qing Liu
- Da-Wo Liu
- Ming-Jun Zheng
- Lu Deng
- Hui-Min Wang
- Shan Jin
- Juan-Juan Liu
- Ying-Ying Hao
- Lian-Cheng Zhu
- Bei Lin
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Shengjing Hospital Affiliated to China Medical University, Shenyang, Liaoning 110000, P.R. China, Department of Obstetrics and Gynecology, University Hospital, LMU Munich, D‑80337 Munich, Germany, Department of Obstetrics and Gynecology, Hospital of Fudan University, Shanghai 200000, P.R. China, Department of Obstetrics and Gynecology, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning 110000, P.R. China
Published online on: May 5, 2021 https://doi.org/10.3892/mmr.2021.12135
Article Number: 496
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the effects of human epididymis protein 4 (HE4) on drug resistance and its underlying mechanisms. The associations among proteins were detected by immunoprecipitation and immunofluorescence assays. Then, stably transfected cell lines CAOV3‑HE4‑L and CAOV3‑A2‑L expressing HE4 short hairpin (sh)RNAs and ANXA2 shRNAs, respectively, were constructed. MTT assay, immunocytochemistry, western blotting, reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and flow cytometry were employed to examine drug sensitivity, as well as the expression and activity of P‑glycoprotein (P‑gp). HE4 and P‑gp in epithelial ovarian cancer tissues were assessed via immunohistochemistry. MicroRNAs that targeted the P‑gp gene, ABCB1, were predicted using bioinformatics methods, and their expression was evaluated by RT‑qPCR. The common signaling pathways shared by HE4, ANXA2 and P‑gp were selected by Gene Set Enrichment Analysis (GSEA). The interaction of HE4, ANXA2 and P‑gp were confirmed. P‑gp expression was positively associated with HE4 and ANXA2 expression, respectively. Moreover, it was observed that there was no significant rescue of P‑gp expression in CAOV3‑A2‑L cells following the administration of active HE4 protein. In addition, the expression of HE4 and P‑gp in ovarian cancer tissues of drug‑resistant patients were higher compared with that of the drug‑sensitive group (P<0.05). Furthermore, the results revealed that hsa‑miR‑129‑5p was significantly increased accompanied by decreased HE4 or ANXA2 expression and P‑gp expression in CAOV3‑HE4‑L and CAOV3‑A2‑L cells. GSEA analyses disclosed that HE4, ANXA2 and P‑gp genes were commonly enriched in the signaling pathway involved in regulating the actin cytoskeleton. These results indicated that HE4 promotes P‑gp‑mediated drug resistance in ovarian cancer cells through the interactions with ANXA2, and the underlying mechanism may be associated with decreased expression of hsa‑miR‑129‑5p and dysregulation of the actin cytoskeleton signaling pathway.

View Figures

View References

1	Kipps E, Tan DS and Kaye SB: Meeting the challenge of ascites in ovarian cancer: New avenues for therapy and research. Nat Rev Cancer. 13:273–282. 2013. View Article : Google Scholar : PubMed/NCBI
2	Baguley BC: Multiple drug resistance mechanisms in cancer. Mol Biotechnol. 46:308–316. 2010. View Article : Google Scholar : PubMed/NCBI
3	Baguley BC: Multidrug resistance in cancer. Methods Mol Biol. 596:1–14. 2010. View Article : Google Scholar : PubMed/NCBI
4	Mechetner EB and Roninson IB: Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci USA. 89:5824–5828. 1992. View Article : Google Scholar : PubMed/NCBI
5	Breier A, Gibalova L, Seres M, Barancik M and Sulova Z: New insight into p-glycoprotein as a drug target. Anticancer Agents Med Chem. 13:159–170. 2013. View Article : Google Scholar : PubMed/NCBI
6	Gibalová L, Sereš M, Rusnák A, Ditte P, Labudová M, Uhrík B, Pastorek J, Sedlák J, Breier A and Sulová Z: P-glycoprotein depresses cisplatin sensitivity in L1210 cells by inhibiting cisplatin-induced caspase-3 activation. Toxicol In Vitro. 26:435–444. 2012. View Article : Google Scholar
7	Hellström I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, Drescher C, Urban N and Hellström KE: The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 63:3695–3700. 2003.
8	Aarenstrup Karlsen M, Høgdall C, Nedergaard L, Philipsen Prahm K, Schou Karlsen NM, Weng Ekmann-Gade A, Henrichsen Schnack T, Svenstrup Poulsen T, Jarle Christensen I and Høgdall E: HE4 as a predictor of adjuvant chemotherapy resistance and survival in patients with epithelial ovarian cancer. APMIS. 124:1038–1045. 2016. View Article : Google Scholar : PubMed/NCBI
9	Nassir M, Guan J, Luketina H, Siepmann T, Rohr I, Richter R, Castillo-Tong DC, Zeillinger R, Vergote I, Van Nieuwenhuysen E, et al: The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study. Tumour Biol. 37:3009–3016. 2016. View Article : Google Scholar : PubMed/NCBI
10	Ribeiro JR, Schorl C, Yano N, Romano N, Kim KK, Singh RK and Moore RG: HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells. J Ovarian Res. 9:282016. View Article : Google Scholar : PubMed/NCBI
11	Tanaka T, Akatsuka S, Ozeki M, Shirase T, Hiai H and Toyokuni S: Redox regulation of Annexin II and its implications for oxidative stress-induced renal carcinogenesis and metastasis. Oncogene. 23:3980–3989. 2004. View Article : Google Scholar : PubMed/NCBI
12	Bjørnland K, Winberg JO, Odegaard OT, Hovig E, Loennechen T, Aasen AO, Fodstad O and Maelandsmo GM: S100A4 involvement in metastasis: Deregulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in osteosarcoma cells transfected with an anti-S100A4 ribozyme. Cancer Res. 59:4702–4708. 1999.
13	Mathisen B, Lindstad RI, Hansen J, El-Gewely SA, Maelandsmo GM, Hovig E, Fodstad O, Loennechen T and Winberg JO: S100A4 regulates membrane induced activation of matrix metalloproteinase-2 in osteosarcoma cells. Clin Exp Metastasis. 20:701–711. 2003. View Article : Google Scholar : PubMed/NCBI
14	Zhuang H, Tan M, Liu J, Hu Z, Liu D, Gao J, Zhu L and Lin B: Human epididymis protein 4 in association with Annexin II promotes invasion and metastasis of ovarian cancer cells. Mol Cancer. 13:2432014. View Article : Google Scholar : PubMed/NCBI
15	Zhang F, Zhang H, Wang Z, Yu M, Tian R, Ji W, Yang Y and Niu R: P-glycoprotein associates with Anxa2 and promotes invasion in multidrug resistant breast cancer cells. Biochem Pharmacol. 87:292–302. 2014. View Article : Google Scholar : PubMed/NCBI
16	Zhang ZD, Li Y, Fan Q, Zhao B, Tan B and Zhao XF: Annexin II is implicated in multi-drug-resistance in gastric cancer through p38MAPK and AKT pathway. Neoplasma. 61:627–637. 2014. View Article : Google Scholar : PubMed/NCBI
17	Li N, Yang L, Wang H, Yi T, Jia X, Chen C and Xu P: MiR-130a and MiR-374a function as novel regulators of cisplatin resistance in human ovarian cancer A2780 Cells. PLoS One. 10:e01288862015. View Article : Google Scholar : PubMed/NCBI
18	Jung H, Kim JS, Kim WK, Oh KJ, Kim JM, Lee HJ, Han BS, Kim DS, Seo YS, Lee SC, et al: Intracellular Annexin II regulates NF-κB signaling by binding to the p50 subunit: Implications for gemcitabine resistance in pancreatic cancer. Cell Death Dis. 6:e16062015. View Article : Google Scholar : PubMed/NCBI
19	Zhang R, Lu M, Zhang Z, Tian X, Wang S and Lv D: Resveratrol reverses P-glycoprotein-mediated multidrug resistance of U2OS/ADR cells by suppressing the activation of the NF-κB and p38 MAPK signaling pathways. Oncol Lett. 12:4147–4154. 2016. View Article : Google Scholar : PubMed/NCBI
20	FIGO Committee on Gynecologic Oncology, . Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. Int J Gynaecol Obstet. 105:3–4. 2009. View Article : Google Scholar : PubMed/NCBI
21	Morgan RJ Jr, Copeland L, Gershenson D, Locker G, McIntosh D, Ozols R and Teng N; The National Comprehensive Cancer Network, : NCCN ovarian cancer practice guidelines. Oncology (Williston Park). 10 (Suppl 11):293–310. 1996.PubMed/NCBI
22	Zhuang H, Gao J, Hu Z, Liu J, Liu D and Lin B: Co-expression of Lewis y antigen with human epididymis protein 4 in ovarian epithelial carcinoma. PLoS One. 8:e689942013. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Wang H, Tan M, Zhang S, Li X, Gao J, Zhang D, Hao Y, Gao S, Liu J and Lin B: Expression and significance of CD44, CD47 and c-met in ovarian clear cell carcinoma. Int J Mol Sci. 16:3391–3404. 2015. View Article : Google Scholar : PubMed/NCBI
25	Moore RG, Hill EK, Horan T, Yano N, Kim K, MacLaughlan S, Lambert-Messerlian G, Tseng YD, Padbury JF, Miller MC, et al: HE4 (WFDC2) gene overexpression promotes ovarian tumor growth. Sci Rep. 4:35742014. View Article : Google Scholar : PubMed/NCBI
26	Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Berek JS, Chen LM, Cristea M, DeRosa M, et al: NCCN guidelines insights: Ovarian cancer, Version 1. J Natl Compr Canc Netw. 17:896–909. 2019. View Article : Google Scholar : PubMed/NCBI
27	Kim VN and Nam JW: Genomics of microRNA. Trends Genet. 22:165–173. 2006. View Article : Google Scholar : PubMed/NCBI
28	Wu Q, Yang Z, Xia L, Nie Y, Wu K, Shi Y and Fan D: Methylation of miR-129-5p CpG island modulates multi-drug resistance in gastric cancer by targeting ABC transporters. Oncotarget. 5:11552–11563. 2014. View Article : Google Scholar : PubMed/NCBI
29	Islam SU, Shehzad A, Sonn JK and Lee YS: PRPF overexpression induces drug resistance through actin cytoskeleton rearrangement and epithelial-mesenchymal transition. Oncotarget. 8:56659–56671. 2017. View Article : Google Scholar : PubMed/NCBI